Radiotoxicity of Platinum-195m-labeled Trans-platinum (II) in Mammalian Cells

Overview

Journal Radiat Res

Specialties Genetics
Radiology

Date 1994 Oct 1

PMID 7938455

Citations 17

Authors

R W Howell

A I Kassis

S J Adelstein

D V Rao

H A WRIGHT

R N Hamm

J E Turner

K S Sastry

Affiliations

Soon will be listed here.

Abstract

The chemotoxicity and radiotoxicity of trans-dichlorodiammineplatinum (II) labeled with 195mPt (trans-195mPt) are investigated to ascertain the potential of radioplatinum coordination complexes as antineoplastic agents. Platinum-195m, with a half-life of about 4 days, is a prolific emitter of low-energy Auger electrons because of the high probability of internal conversion in its isomeric transitions. The kinetics of cellular uptake and retention after incubation and the radiotoxicity of this Auger electron emitter in the form of trans-195mPt is investigated using cells of the Chinese hamster V79 cell line. The cellular uptake of 195mPt reaches a plateau in about 3 to 5 h of incubation and varies nonlinearly with the extracellular concentration of radioactivity. The radioactivity is eliminated from the cells after incubation with an effective half-life of 24 h. Cell survival data, when corrected for the chemical toxicity of nonradiolabeled trans-platinum, give a cell survival curve typical for radiations with high linear energy transfer. At 37% survival, the mean lethal cellular uptake is about 1.0 mBq/cell. Dosimetric considerations, based on subcellular distribution of the radionuclide, yield a value of 4.8 for the relative biological effectiveness when compared with 250 kVp X rays. Theoretical Monte Carlo track-structure calculations indicate that the density of radical species produced in liquid water in the immediate vicinity of a 195mPt decay site is substantially greater than the density of species along the track of a 5.3 MeV alpha particle. This explains qualitatively the efficacy of 195mPt in causing high-LET radiation type biological effects. The extreme radiotoxicity of intranuclearly localized 195mPt, in conjunction with the proclivity of platinum chemotherapy agents to bind to DNA in the cell nucleus, suggests that the combination of chemical effects and the effects of Auger electrons that can be obtained with radioplatinum coordination complexes may have potential in the treatment of cancer.

Citing Articles

MIRD Pamphlet No. 31: MIRDcell V4-Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy.

Katugampola S, Wang J, Howell R J Nucl Med. 2024; 65(12):1965-1973.

PMID: 39448267 PMC: 11619582. DOI: 10.2967/jnumed.123.267238.

Recent Advances on Pt-Based Compounds for Theranostic Applications.

Ferrari G, Lopez-Martinez I, Wanek T, Kuntner C, Montagner D Molecules. 2024; 29(15).

PMID: 39124859 PMC: 11313463. DOI: 10.3390/molecules29153453.

Searching for a Paradigm Shift in Auger-Electron Cancer Therapy with Tumor-Specific Radiopeptides Targeting the Mitochondria and/or the Cell Nucleus.

Fernandes C, Palma E, Silva F, Belchior A, Pinto C, Guerreiro J Int J Mol Sci. 2022; 23(13).

PMID: 35806239 PMC: 9266350. DOI: 10.3390/ijms23137238.

Development of Novel Pt-Labeled Hoechst33258: Pt Is More Suitable than In for Targeting DNA.

Obata H, Tsuji A, Kumata K, Sudo H, Minegishi K, Nagatsu K J Med Chem. 2022; 65(7):5690-5700.

PMID: 35358392 PMC: 9014856. DOI: 10.1021/acs.jmedchem.1c02209.

Design, Synthesis, and Cytotoxicity Assessment of [Cu]Cu-NOTA-Terpyridine Platinum Conjugate: A Novel Chemoradiotherapeutic Agent with Flexible Linker.

Khosravifarsani M, Ait-Mohand S, Paquette B, Sanche L, Guerin B Nanomaterials (Basel). 2021; 11(9).

PMID: 34578470 PMC: 8469169. DOI: 10.3390/nano11092154.

References

Kassis A, Harris C, Adelstein S, Ruth T, Lambrecht R, Wolf A . The in vitro radiobiology of astatine-211 decay. Radiat Res. 1986; 105(1):27-36. View

Rao D, Sastry K, Govelitz G, Grimmond H, Hill H . In vivo effects of iron-55 and iron-59 on mouse testes: biophysical dosimetry of Auger electrons. J Nucl Med. 1985; 26(12):1456-65. View

Kassis A, Van den Abbeele A, Wen P, Baranowska-Kortylewicz J, Aaronson R, DeSisto W . Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res. 1990; 50(16):5199-203. View

Desombre E, Mease R, Hughes A, Harper P, Dejesus O, Friedman A . Bromine-80m-labeled estrogens: Auger electron-emitting, estrogen receptor-directed ligands with potential for therapy of estrogen receptor-positive cancers. Cancer Res. 1988; 48(4):899-906. DOI: 10.2172/6347502. View

De Spiegeleer B, Slegers G, van den Bossche W, de Moerloose P . Quantitative analysis of cis-dichlorodiammineplatinum(II) by high-performance thin-layer chromatography. J Chromatogr. 1984; 315:481-7. DOI: 10.1016/s0021-9673(01)90774-5. View

Hofer K, Keough G, Smith J . Biological toxicity of Auger emitters: molecular fragmentation versus electron irradiation. Curr Top Radiat Res Q. 1978; 12(1-4):335-54. View

Baranowska-Kortylewicz J, Makrigiorgos G, Van den Abbeele A, Berman R, Adelstein S, Kassis A . 5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys. 1991; 21(6):1541-51. DOI: 10.1016/0360-3016(91)90331-w. View

Howell R, Narra V, Sastry K, Rao D . On the equivalent dose for Auger electron emitters. Radiat Res. 1993; 134(1):71-8. PMC: 3690377. View

Narra V, Howell R, Thanki K, Rao D . Radiotoxicity of 125I-iododeoxyuridine in pre-implantation mouse embryos. Int J Radiat Biol. 1991; 60(3):525-32. DOI: 10.1080/09553009114552361. View

10.

Kassis A, Fayad F, Kinsey B, Sastry K, Adelstein S . Radiotoxicity of an 125I-labeled DNA intercalator in mammalian cells. Radiat Res. 1989; 118(2):283-94. View

11.

Rao D, Narra V, Howell R, Govelitz G, Sastry K . In-vivo radiotoxicity of DNA-incorporated 125I compared with that of densely ionising alpha-particles. Lancet. 1989; 2(8664):650-3. PMC: 8172252. DOI: 10.1016/s0140-6736(89)90896-9. View

12.

Bloomer W, McLaughlin W, Milius R, Weichselbaum R, Adelstein S . Estrogen receptor-mediated cytotoxicity using iodine-125. J Cell Biochem. 1983; 21(1):39-45. DOI: 10.1002/jcb.240210106. View

13.

Rao D, Sastry K, Grimmond H, Howell R, Govelitz G, Lanka V . Cytotoxicity of some indium radiopharmaceuticals in mouse testes. J Nucl Med. 1988; 29(3):375-84. View

14.

Hofer K, HUGHES W . Radiotoxicity of intranuclear tritium, 125 iodine and 131 iodine. Radiat Res. 1971; 47(1):94-101. View

15.

Narra V, Howell R, Harapanhalli R, Sastry K, Rao D . Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design. J Nucl Med. 1992; 33(12):2196-201. View

16.

Kassis A, Sastry K, Adelstein S . Intracellular distribution and radiotoxicity of chromium-51 in mammalian cells: Auger-electron dosimetry. J Nucl Med. 1985; 26(1):59-67. View

17.

Kassis A, Sastry K, Adelstein S . Kinetics of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res. 1987; 109(1):78-89. View

18.

Rao D, Narra V, Howell R, Sastry K . Biological consequence of nuclear versus cytoplasmic decays of 125I: cysteamine as a radioprotector against Auger cascades in vivo. Radiat Res. 1990; 124(2):188-93. View

19.

Kassis A, Adelstein S . A rapid and reproducible method for the separation of cells from radioactive media. J Nucl Med. 1980; 21(1):88-90. View

20.

Bagshawe K, Sharma K, Southall P, Boden J, Boxer G, Patridge T . Selective uptake of toxic nucleoside (125IUdR) by resistant cancer. Br J Radiol. 1991; 64(757):37-44. DOI: 10.1259/0007-1285-64-757-37. View